the real issue is early detection of the disease. They propose women not be diagnosed early because there is access to very expensive chemotherapy treatment with short and long lasting physical, cognitive, emotional and psychological damage; also, the advanced stage of the disease causes real human suffering. Their comments about the impact of treatment are speculation taken from thin air, without any supporting data. Without individual patient data nobody can tell the relative benefit of treatment versus screening, and none of those authors who are against screening have access to individual patient data! In their Editorial they mention the Canadian trials that have been declared a "national embarrassment" by Dr. Paula Gordon, professor of Radiology in Vancouver, Canada, but do not give proper credit to the eight truly population based randomized controlled trials. This is a biased selection of the relevant literature.
Their comment "The Norwegian study largely confirms what is already known: the benefits of screening mammography are modest at best" is interesting. In contrast to the Norwegian authors, Elmore and Russell Harris do not appear to understand the difference between "screening" (i.e. attending screening) and "invitation to screening"; had they read the article carefully, they would have realized that "Attendance was associated with a 37% lower risk" of dying from breast cancer. Calling these results "modest at best" speaks for itself. Elmore and Harris should have written about the "harms and benefits" of mammography screening in a more balanced way such as: The potential harm of attending versus the real harm of not attending mammography screening. I strongly recommend that Drs. László Tabár, MD
